Log in
Enquire now
Oxford Genetics

Oxford Genetics

Oxford Genetics, also known as Oxgene, is a synthetic biology company specializing in DNA design, protein expression optimization and cell line development technologies and services.

OverviewStructured DataIssuesContributors

Contents

oxgene.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biopharmaceutical
Biopharmaceutical
Genetics
Genetics
Biomedical engineering
Biomedical engineering
‌
Genome editing
Genomics
Genomics
Biology
Biology
...
Location
United Kingdom
United Kingdom
Oxford
Oxford
Oxfordshire
Oxfordshire
B2X
B2B
B2B
CEO
Ryan Cawood
Ryan Cawood
Founder
Leonard Seymour
Leonard Seymour
Ryan Cawood
Ryan Cawood
Legal Name
Oxford Genetics Ltd.
Legal classification
Limited company
Limited company
Date Incorporated
April 28, 2011
Number of Employees (Ranges)
51 – 200
Full Address
Medawar Centre Robert Robinson Avenue Oxford OX4 4GA England, United Kingdom
Investors
‌
Mercia Asset Management PLC
UK Research & Innovation (UKRI)
UK Research & Innovation (UKRI)
‌
Invesco Perpetual
Mercia Fund Management
Mercia Fund Management
Founded Date
2011
0
Total Funding Amount (USD)
31,419,005
Latest Funding Round Date
April 2019
Competitors
Oxford Drug Design Limited
Oxford Drug Design Limited
Glassdoor ID
1538328
Acquisition Transaction
‌
Acquisition of Oxford Genetics by WuXi AppTec
Also Known As
Oxgene
Latest Funding Type
Series A
Series A
Patents Assigned (Count)
1
Technologies Used
CRISPR
CRISPR
Country
United Kingdom
United Kingdom

Other attributes

Blog
oxgene.com/news_and_views/news
Company Operating Status
Active
Latest Funding Round Amount (USD)
9,080,792

Oxford Genetics is a leading synthetic biology company focused on developing technologies to associated with the discovery, development and production of biologics, gene therapies, cell therapies and vaccines.

License agreement

In September 2018, Oxford Genetics and ERS Genomics extended their pre-existing non-exclusive, license agreement for the use of CRISPR gene editing technology. The agreement, which previously allowed Oxford Genetics to supply CRISPR modified cell lines to the US and Europe, has been extended to include the Asia Pacific region.

Funding
Growth

In August 2018, Oxford Genetics secured a $9.6m investment. The investment comes from existing investor Mercia Technologies PLC and Invesco Perpetual. A spokesperson from Oxford Genetics made the following statement regarding the investment:

This will allow us to continue to exeed regulatory requirements and provide quality assurance for our clients. We will also add more analytical, purification and process development equipment, for instance small scale bioreactors, to enable us to fully support our clients from research up to the point of GMP bioproduction.
Series A

On March 28, 2019 Oxford Genetics completed their series A funding round with £6.5 million in funding from Canaccord Genuity Limited, Invesco Asset Management Limited, and Merica. The CEO and founder of Oxford Genetics, Ryan Cawood, made the following statement following the companies successful series A funding round:

This significant investment round will enable Oxford Genetics to further secure its market-leading position in the expanding fields of CRISPR, gene therapy and antibody engineering.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Oxford Genetics

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.